IFNG and non-small cell lung carcinoma: A similar study (phase II clinical trial) was conducted by Besse et al. to evaluate the clinical benefit of IFN-γ-Dex loaded with MHC class I and class II-restricted cancer antigens from patients with non-small-cell lung cancer (NSCLC).